Dow Jones
31.037,68 +69,86 (+0,23%) Nasdaq
11.361,85 +39,61 (+0,35%) Nikkei 225
26.107,65 -315,82 (-1,20%) EUR/USD
1,0193 -0,0077 (-0,75%) BTC-EUR
20.124,16 -21,68 (-0,11%) CMC Crypto 200
440,40 +4,88 (+1,12%)
Pfizer Inc. (PFE)
Dopo ore:
| Chiusura precedente | 51,64 |
| Aperto | 51,64 |
| Denaro | 52,60 x 1200 |
| Lettera | 52,77 x 1300 |
| Min-Max giorno | 51,58 - 52,96 |
| Intervallo di 52 settimane | 38,93 - 61,71 |
| Volume | |
| Media Volume | 24.286.780 |
| Capitalizzazione | 295,975B |
| Beta (5 anni mensile) | 0,71 |
| Rapporto PE (ttm) | 11,88 |
| EPS (ttm) | 4,44 |
| Prossima data utili | 28 lug 2022 |
| Rendimento e dividendo (forward) | 1,60 (3,10%) |
| Data ex dividendo | 28 lug 2022 |
| Stima target 1A | 58,62 |
- GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting either aloneA single registrational Phase 3 trial evaluating oral brepocitinib in derm
- GlobeNewswire
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in over 1,200 women with moderate to severe pain associated with endometriosis were published in The Lancet. As previously reported, both studies achieved their co-prim
- GlobeNewswire
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing
